Angle Health
About Angle Health
Angle Health is a Healthtech startup based in United States. The company reached Series C stage in September 2026 with a $600M round led by Vitruvian Partners at a $2.7B valuation. Angle Health's investor base includes 6 institutional funds, with Vitruvian Partners leading the most recent equity round.
Angle Health is a US-based AI-native health insurance platform purpose-built for small and mid-sized businesses. Its full-stack system combines a licensed insurance carrier with an AI-enabled benefits management platform, offering employers comprehensive, customizable healthcare coverage that adapts to each employee's needs. The platform displaces traditional fully-insured plans with a level-funded model — giving employers cost predictability and claims transparency — while reducing administrative burden through automation. A Y Combinator alumnus, Angle Health reached a $2.7 billion valuation on a $600 million Series C round led by Vitruvian Partners, representing one of the largest healthtech raises of 2026.
Angle Health Funding Rounds Timeline
1 rounds
| Round | Date | Amount | Valuation | Lead investor | Co-investors |
|---|---|---|---|---|---|
| Series C | September 2026 | $600M | $2.7B | Vitruvian Partners | Town Hall Ventures, Blumberg Capital, Portage, PruVen Capital, Y Combinator |
Investors in Angle Health
6 institutional investors across 1 rounds
Lead investors
Co-investors
Recent news about Angle Health
- FundingAngle Health Raises $600 Million At $2.7 Billion Valuation To Expand AI-Native Healthcare Benefits PlatformSeptember 2026
- FundingAngle Health Raises $600M at a $2.7B ValuationSeptember 2026
Questions about Angle Health
How much has Angle Health raised?
Angle Health has raised null across 1 funding round since null.
Who are the investors of Angle Health?
Angle Health's investors include Vitruvian Partners, Town Hall Ventures, Blumberg Capital, Portage, PruVen Capital, Y Combinator.
When was Angle Health's last funding round?
Angle Health's most recent round was a $600M Series C in September 2026, led by Vitruvian Partners.